Fludarabine
Gynecologic Cancer
Masonic Cancer Center, University of MinnesotaSmall moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
51 Active assets in the Gynecologic Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inno-206 AstraZeneca | Phase 2 | BB |
Carboplatin AbbVie | Phase 2/3 | BB |
Indocyanine Green Istanbul University | Phase 4 | BB |
Ipilimumab M.D. Anderson Cancer Center | Phase 2 | B |
Atezolizumab M.D. Anderson Cancer Center | Phase 2 | B |
View all 50 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →